Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
April 27 2023 - 8:30AM
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage
precision oncology company, today announced that company executives
will participate in three upcoming healthcare investment
conferences.
Details are as follows:
- H. C. Wainwright BioConnect
Investor Conference at Nasdaq Kris Vaddi, Ph.D., Chief
Executive Officer will participate in a fireside chat on Tuesday,
May 2, at 1:30 p.m. ET. The live webcast is available here. The
Company will also host one-on-one investor meetings during the
day.
- Bank of America Securities
2023 Healthcare Conference Jane Huang, MD, President and
Chief Medical Officer and Laurent Chardonnet, Chief Financial
Officer, will conduct one-on-one meetings on Wednesday, May 10 and
Thursday May 11. Dr. Huang will participate in a fireside chat on
May 10 at 4:20 p.m. PT/7:20 p.m. ET. The live webcast will be
available here, and will be available for replay until August 11,
2023.
- JMP Securities Life
Sciences ConferenceDr. Vaddi and Mr. Chardonnet will
conduct one-on-one meetings on Monday, May 15 and Tuesday May 16
and Dr. Vaddi will participate in a fireside chat at 12 noon ET, on
May 15. The live webcast is available here and will be available
for replay for 90 days.
About Prelude
Therapeutics Prelude Therapeutics is a clinical-stage
precision oncology company developing innovative drug candidates
targeting critical cancer cell pathways. The Company’s diverse
pipeline is comprised of highly differentiated, potentially
best-in-class or first-in-class proprietary small molecule
compounds aimed at addressing clinically validated pathways
for cancers with selectable underserved patients. Prelude’s
pipeline includes four candidates currently in clinical
development: PRT1419, a potent, selective inhibitor of MCL1,
PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a
next generation CDK4/6 inhibitor, and PRT3789, an
IV administered, potent and highly selective SMARCA2 degrader.
For more information, visit our website and
follow us on LinkedIn and Twitter.
Investor Contact: Lindsey
Trickett Vice President, Investor
Relations 240.543.7970 ltrickett@preludetx.com
Media Contact: Helen Shik
Shik Communications
617.510.4373Helen@ShikCommunications.com
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Apr 2023 to Apr 2024